ロード中...
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...
保存先:
| 出版年: | Mol Cell Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4905349/ https://ncbi.nlm.nih.gov/pubmed/27308505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1008291 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|